12,567 Abbott Laboratories $ABT Shares Sold by Sterling Capital Management LLC

Sterling Capital Management LLC cut its stake in Abbott Laboratories (NYSE:ABT) by 6.1% in the 3rd quarter, Holdings Channel reports. The fund owned 194,734 shares of the healthcare product maker’s stock after selling 12,567 shares during the quarter. Sterling Capital Management LLC’s holdings in Abbott Laboratories were worth $19,246,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. James Investment Research Inc. raised its position in Abbott Laboratories by 10.7% in the 3rd quarter. James Investment Research Inc. now owns 31,592 shares of the healthcare product maker’s stock worth $3,122,000 after purchasing an additional 3,065 shares during the period. WASHINGTON TRUST Co boosted its position in Abbott Laboratories by 0.6% during the third quarter. WASHINGTON TRUST Co now owns 134,334 shares of the healthcare product maker’s stock valued at $13,276,000 after buying an additional 763 shares during the period. XXI Wealth LLC grew its stake in shares of Abbott Laboratories by 10.7% during the third quarter. XXI Wealth LLC now owns 17,642 shares of the healthcare product maker’s stock valued at $1,744,000 after buying an additional 1,705 shares during the last quarter. River Street Advisors LLC grew its stake in shares of Abbott Laboratories by 2.5% during the third quarter. River Street Advisors LLC now owns 12,717 shares of the healthcare product maker’s stock valued at $1,257,000 after buying an additional 316 shares during the last quarter. Finally, Private Wealth Partners LLC increased its holdings in shares of Abbott Laboratories by 2.5% in the third quarter. Private Wealth Partners LLC now owns 16,217 shares of the healthcare product maker’s stock worth $1,603,000 after buying an additional 400 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New data presented at the European Society for Medical Oncology showed Abbott’s whole-genome sequencing Oncodetect® test delivered a 30% absolute improvement in sensitivity for detecting colorectal-cancer recurrence within two years of surgery. Patients with detectable molecular residual disease also faced a 10.6-fold higher recurrence risk, supporting the test’s clinical value and Abbott’s broader cancer-care strategy. Abbott Oncodetect ESMO data
• Positive Sentiment: Wells Fargo upgraded its stance to “overweight” and raised its price target to $119, while other analysts retained buy or outperform ratings. These targets imply substantial potential upside and suggest Wall Street views the recent pullback as excessive. Wells Fargo rating
• Neutral Sentiment: Abbott’s pacemaker and molecular-diagnostics markets are projected to grow, providing long-term demand opportunities. However, the reports also identify procedure costs, regulatory hurdles, cybersecurity risks and changing disease prevalence as industry constraints. Pacemaker market forecast
• Negative Sentiment: Investors remain concerned about Abbott’s lowered 2026 sales-growth outlook. Management cited diabetes-related pricing pressure and weakness in the electrophysiology portfolio, issues that overshadowed a third-quarter earnings and revenue performance that broadly met expectations. Abbott 2026 guidance
• Negative Sentiment: Abbott plans to spin off its approximately $8.5 billion Nutrition business by 2027. Although the transaction could sharpen the company’s focus and unlock value, investors face near-term uncertainty over separation costs, portfolio mix and the growth profile of the remaining business. Abbott Nutrition spin-off
• Negative Sentiment: A comparative study claimed Catheter Precision’s LockeT device outperformed Abbott’s Perclose vascular-closure system. The potential competitive risk appears limited without evidence of meaningful revenue impact, but it adds pressure to Abbott’s medical-device franchise. LockeT and Perclose study

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ABT. Wells Fargo & Company boosted their target price on Abbott Laboratories from $112.00 to $119.00 and gave the company an “overweight” rating in a research note on Thursday. Citigroup decreased their price target on Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating on the stock in a research note on Thursday. Piper Sandler reiterated an “overweight” rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. JPMorgan Chase & Co. dropped their price objective on Abbott Laboratories from $120.00 to $118.00 and set an “overweight” rating for the company in a research note on Thursday. Finally, BTIG Research cut their target price on shares of Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating on the stock in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $118.32.

Abbott Laboratories Trading Up 1.2%

Shares of ABT traded up $1.19 during mid-day trading on Friday, hitting $103.70. 10,296,676 shares of the company’s stock traded hands, compared to its average volume of 10,068,537. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $179.45 billion, a P/E ratio of 38.70, a PEG ratio of 1.90 and a beta of 0.59. The business’s 50-day moving average price is $105.15 and its 200-day moving average price is $98.32. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $132.02.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting analysts’ consensus estimates of $1.42. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The company had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. During the same quarter last year, the firm posted $1.30 earnings per share. The firm’s revenue was up 14.5% on a year-over-year basis. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 annualized dividend and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio is 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.